Market News

• Huberman Lab Drops 3-Hour Peptides Masterclass With Dr. Abud Bakri

  Huberman Lab aired a three-hour peptide deep dive with Dr. Abud Bakri on BPC-157, GHK-Cu, epitalon, GLP-1s, and the evidence gap driving todays peptide boom.

  Jun 1, 2026

• CordenPharma Acquires AmbioPharm in Major Peptide CDMO Expansion

  CordenPharma acquires AmbioPharm, adding two peptide API facilities (U.S. and China) with 400 employees, as peptide manufacturing becomes a strategic priority.

  May 26, 2026

• Fox News Examines 'Wild West' Peptide Craze as FDA Faces Pressure

  Dr. Alex Tatem tells Fox News the peptide market boom poses risks and opportunities as the FDA weighs rule changes on several peptides this summer.

  May 21, 2026

• Parabilis Medicines Files IPO After $2.3B Regeneron Peptide Alliance

  Cambridge peptide biotech Parabilis debuts on Nasdaq after landing a $2.3 billion Regeneron partnership and posting 74% tumor response in Phase 1/2 trials.

  May 20, 2026

• Vector Sciences Inks Peptide Manufacturing Deal for $80.8B Market

  Vector Sciences and MPP Group partner to produce 22 shelf-stable peptides in a cGMP facility — the first major deal since the April FDA reclassification.

  May 19, 2026

• Media Surge: Forbes, Men's Health Call for Peptide Oversight

  Forbes warns peptides went mainstream without safeguards, as Men's Health reviews 100+ studies and Men's Fitness highlights BPC-157 research.

  May 18, 2026

• Men in Their 40s Driving the Peptide Therapy Boom, New Reports Show

  Men's Health and other outlets document surging interest from midlife men as the peptide boom broadens beyond biohackers, outrunning regulatory guardrails.

  May 14, 2026

• Peptide Revolution Reaches The Times, Oprah Daily, Globe and Mail

  The Times examines the injectable peptide industry — joining Oprah Daily, the Globe and Mail, and Glossy in a global mainstream coverage wave.

  May 12, 2026

• Media Wave Converges on Unapproved Peptide Injections — WSJ, SciAm, FT

  WSJ, Scientific American, FT, and The Conversation all covered unapproved peptide injections in one week — a media turning point for the peptide debate.

  May 7, 2026

• The Peptide Problem: Major Media Outlets Question Hype vs. Evidence

  Major media outlets question whether demand for peptide therapies has outpaced the science behind them, ahead of a critical FDA review in July.

  May 6, 2026

• Post-April 15, Where You Live Matters More Than You Think

  Federal peptide reclassification sets the floor; state pharmacy boards set the ceiling. Ten states plus DC keep restrictive regimes that add real friction.

  Apr 29, 2026

• The Telehealth Brands Most Likely to Pivot Into Peptides After PCAC

  GLP-1 telehealth providers have the prescribers, compounding ties, and DTC marketing muscle to dominate peptides after PCAC. Who's positioning, and the impact.

  Apr 28, 2026

• Compounding Pharmacies Quietly Positioning Ahead of July PCAC Meeting

  The 90 days between the April 15 peptide reclassification and the July PCAC meeting are when the supply chain repositions. What's happening, and why it matters.

  Apr 24, 2026